Addition of prothrombin to plasma can result in a paradoxical increase in activated partial thromboplastin time

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 8, 2014, Pages 854-855

  Hansson, Kenny M ^a   Björkqvist, Jenny ^b   Deinum, Johanna ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Activated partial thromboplastin time; Coagulation; Ellagic acid; Kaolin; Prothrombin; Silica

Indexed keywords

ACTIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; CALCIUM ION; ELLAGIC ACID; KAOLIN; PROTHROMBIN; SILICON DIOXIDE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; RECOMBINANT PROTEIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; COMPARATIVE STUDY; CONTAMINATION; CONTROLLED STUDY; GENE MUTATION; HUMAN; IN VITRO STUDY; MICHAELIS MENTEN KINETICS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; STEADY STATE; TITRIMETRY; TURBIDIMETRY; TURNOVER TIME; VISCOMETRY; CHEMISTRY; KINETICS; PHOTOMETRY; PLASMA; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; ELLAGIC ACID; HUMANS; INDICATORS AND REAGENTS; KINETICS; NEPHELOMETRY AND TURBIDIMETRY; PARTIAL THROMBOPLASTIN TIME; PLASMA; PROTHROMBIN; RECOMBINANT PROTEINS; SILICON DIOXIDE; THROMBELASTOGRAPHY;

EID: 84927689209     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000161     Document Type: Article

References (27)

1. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
2. Hemker CH, Béguin S. Phenotyping the clotting system. Thromb Haemost 2000;84:740-934.
3. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964;202:498-499.
4. Pokhilko AV. Intrinsic Coagulation Pathway: An Activation Threshold. Thromb Res 2000;99:285-293.
5. Kitchen S, Cartwright I, Woods TAL, Jennings I, Preston FE. Lipid composition of seven APTT reagents in relation to heparin sensitivity. Br J Haematol 1999;106:801-808.
6. Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Sem Thromb Hemost 1999;25:407-418.
7. Park K-J, Kwon E-H, Ma Y, Park I-A, Kim S-W, Kim S-H, et al. Significantly different coagulation factor activities underlying the variability of 'normal' activated partial thromboplastin time. Blood Coagul Fibrinolysis 2012;23:35-38.
8. De Visser MCH, Van Hylckama Vlieg A, Tans G, Rosing J, Dahm AEA, Sandset PM, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005;3:1488-1494.
9. Bowyer A, Kitchen S, Makris M. The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies. Int J Lab Hematol 2011;33:154-158.
10. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol 1993;100:94-98.
11. Lawrie AS, Kitchen S, Purdy G, Mackie IJ, Preston FE, Machin SJ. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies. Clin Lab Haematol 1998;20:179-186.
12. Marlar RA, Bauer PJ, Endres-Brooks JL, Montgomery RR, Miller CM, Schanen MM. Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies. Am J Clin Pathol 1984;82:436-439.
13. Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson A, et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 2005;115:9-18.
14. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-139.
15. Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996;49:10-14.
16. Zanke B, Shojania AM. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma. Am J Clin Pathol 1990;93:684-689.
17. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 2013;26:191-202.
18. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001;101:145-157.
19. Mitterlechner T, Innerhofer P, Streif W, Lödi M, Danninger T, Klima G, et al. Prothrombin complex concentrate and recombinant prothrombin alone orin combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J Thromb Haemost 2011;9:729-737.
20. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemast 1997;78:1286-1292.
21. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost 2002;87:614-621.
22. Walker RK, Krishnaswamy S. The activation of prothrombin by the prothrombinase complex. The contribution of the substrate-membrane interaction to catalysis. J Biol Chem 1994;269:27441-27450.
23. Brufatto N, Nesheim ME. Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process. J Biol Chem 2003;278:6755-6764.
24. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988;263:3823-3834.
25. Giesen PL, Willems GM, Hermens WT. Production of thrombin by the prothrombinase complex is regulated by membrane-mediated transport of prothrombin. J Biol Chem 1991;266:1379-1382.
26. Vicente V, Gonzalez-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematology 1999;84:356-362.
27. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011;15:201.